There is a newer version of the record available.

Published 2024 | Version v1
Journal article

Validating the safety of low-dose CTPA in pregnancy: results from the OPTICA (Optimised CT Pulmonary Angiography in Pregnancy) Study

  • 1. Department of Radiology, Mater Misericordiae University Hospital, Whitty Building, North Circular Road, Dublin 7, D07 R2WY, Dublin (Ireland)
  • 2. Department of Haematology, Mater Misericordiae University Hospital, D07 R2WY, Dublin (Ireland)
  • 3. Department of Obstetrics, Rotunda Hospital, D01 P5W9, Dublin (Ireland)
  • 4. Clinical Research Centre, School of Medicine, University College Dublin, D04 V1W8, Dublin (Ireland)
  • 5. School of Medicine, University College Dublin, D04 V1W8, Dublin (Ireland)
  • 6. Department of Medical Physics, St James Hospital, D08 NHY1, Dublin (Ireland)
  • 7. Radiography & Diagnostic Imaging, School of Medicine, University College Dublin, D04 V1W8, Dublin (Ireland)

Description

Pulmonary embolism (PE) is a leading cause of pregnancy-related mortality. CT pulmonary angiogram (CTPA) is the first-line advanced imaging modality for suspected PE in pregnancy at institutes offering low-dose techniques; however, a protocol balancing safety with low dose remains undefined. The wide range of CTPA doses reported in pregnancy suggests a lack of confidence in implementing low-dose techniques in this group. To define and validate the safety, radiation dose and image quality of a low-dose CTPA protocol optimised for pregnancy. The OPTICA study is a prospective observational study. Pregnant study participants with suspected PE underwent the same CTPA protocol between May 2018 and February 2022. The primary outcome, CTPA safety, was judged by the reference standard; the 3-month incidence of venous thromboembolism (VTE) in study participants with a negative index CTPA. Secondary outcomes defined radiation dose and image quality. Absorbed breast, maternal effective and fetal doses were estimated by Monte-Carlo simulation on gestation-matched phantoms. Image quality was assessed by signal-to-noise and contrast-to-noise ratios and a Likert score for pulmonary arterial enhancement. A total of 116 CTPAs were performed in 113 pregnant women of which 16 CTPAs were excluded. PE was diagnosed on 1 CTPA and out-ruled in 99. The incidence of recurrent symptomatic VTE was 0.0% (one-sided 95% CI, 2.66%) at follow-up. The mean absorbed breast dose was 2.9 ± 2.1 mGy, uterine/fetal dose was 0.1 ± 0.2 mGy and maternal effective dose was 1.4 ± 0.9 mSv. Signal-to-noise ratio (SNR) was 11.9 ± 3.7. Contrast-to-noise ratio (CNR) was 10.4 ± 3.5. The OPTICA CTPA protocol safely excluded PE in pregnant women across all trimesters, with low fetal and maternal radiation. OPTICA (Optimised CT Pulmonary Angiography in Pregnancy) is the first prospective study to define the achievable radiation dose, image-quality and safety of a low-dose CT pulmonary angiogram protocol optimised for pregnancy (NCT04179487). It provides the current benchmark for safe and achievable CT pulmonary angiogram doses in the pregnant population.

Additional details

Identifiers

Publishing Information

Journal Title
European Radiology (Internet)
Journal Volume
34
Journal Issue
8
Journal Page Range
p. 4864-4873
ISSN
1432-1084
CODEN
EURAE3